Detailed Information on Publication Record
2018
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
PAVLASOVÁ, Gabriela, Marek BORSKÝ, Veronika SVOBODOVÁ, Jan OPPELT, Kateřina AMRUZ ČERNÁ et. al.Basic information
Original name
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
Authors
PAVLASOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Veronika SVOBODOVÁ, Jan OPPELT (203 Czech Republic, belonging to the institution), Kateřina AMRUZ ČERNÁ (203 Czech Republic, belonging to the institution), Jitka NOVOTNÁ (203 Czech Republic, belonging to the institution), Kateřina MUSILOVÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Eva VOJÁČKOVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek MRÁZ (203 Czech Republic, guarantor, belonging to the institution)
Edition
AACR Annual Meeting Chicago Illinois USA, 2018
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
10606 Microbiology
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14740/18:00104003
Organization unit
Central European Institute of Technology
Keywords in English
CD20; BCR; CLL
Tags
Změněno: 26/3/2019 15:25, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo, CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo.
Links
LQ1601, research and development project |
| ||
MUNI/A/0968/2017, interní kód MU |
| ||
MUNI/H/0865/2016, interní kód MU |
| ||
NV16-29622A, research and development project |
| ||
692298, interní kód MU |
|